Guanabenz and methyldopa on hypertension and cardiac performance

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Guanabenz demonstrated safety and efficacy as an antihypertensive agent in prior studies.
• Guanabenz exhibits no acute adverse effects on cardiac function.

Purpose of the Study:

• To conduct a double-blind comparison of guanabenz and methyldopa in managing hypertension.
• To evaluate the long-term efficacy and safety of guanabenz.

Main Methods:

• A 6-month double-blind trial involving 36 hypertensive patients comparing guanabenz and methyldopa.
• Noninvasive techniques were used to assess cardiac performance.
• An additional 6-month open-label phase for patients on guanabenz.

Main Results:

• Both guanabenz and methyldopa significantly reduced blood pressure with comparable side effects.
• Methyldopa therapy led to positive Coombs' tests in 3 patients and adverse cardiac effects (increased QS2 and PEP/LVET).
• Guanabenz showed continued efficacy and safety over 12 months without adverse cardiac effects.

Conclusions:

• Guanabenz is an effective antihypertensive drug with a favorable safety profile.
• Guanabenz offers therapeutic advantages over methyldopa, particularly regarding cardiac function.
• Guanabenz represents a significant new option for hypertension management.